|
Good morning subscribers!
Hope you got our email last night on PSID. If you missed it, we got your back!
Check it out below, it's looking hot guys!
Reading up on PSID has us very excited!
Keep an eye on this one folks we think huge things may happen!
Our new pick for tonight is PSID!
They had big news out last week (which is included below) and We feel like this could be a prime time for our members to hop in!
PSID: Positive ID Corporation- something we can stand behind!
Positive ID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio! Positive ID Develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays! Positive ID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security!
BIG NEWS THAT CAME OUT LAST WEEK:
Last week on Yahoo- big news came out on PSID.
It stated- Positive ID Reports 2015 Revenue of $2.9 million , up 211% Year over Year! Total Assets Increase 360% to $4.7 million. Their revenue and total assets increased significantly in 2015, all the while continuing to invest in research and development. PSID stated, “With our continued growth and horizontal integration of our business, we are reaffirming our 2016 revenue guidance of $5-6 Million.”
TECHNOLOGY:
PositiveID develops biological detection and diagnostics systems, including its M-BAND and Firefly Dx systems, which use real-time polymerase chain reaction (PCR) chemistry. PCR amplifies a sample’s DNA and copies it billions of times. PCR is used every day to diagnose diseases, identify bacteria and viruses, and for many other applications. With real-time PCR, the amplification of the DNA can be measured as it occurs, thereby speeding up the ability to deliver results. Real-time PCR is one of the most sensitive and specific bio-detection capabilities available today. PositiveID's microfluidic technology replaces robotics with integrated microfluidics, reducing cost and increasing reliability. Its microfluidic technology also automates and increases the effectiveness of key sample processing steps used today on the laboratory bench-top, into a closed, automated system. The embedded devices perform cell lysis (including difficult spores) in less than one minute at low power, nucleic acid purification along with inhibitor removal and pre-concentration of the nucleic acids up to factors of 1000X within minutes. These processes all occur autonomously within a fully contained disposable microfluidic cartridge.
BUSINESS DESCRIPTION:
PositiveID Corporation develops molecular diagnostic systems for bio-threat detection and rapid medical testing. The Company's proprietary airborne pathogen detection system called M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), continuously and autonomously analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins. PositiveID's Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time polymerase chain reaction (PCR) chemistry. Firefly Dx is being developed to meet the growing need in healthcare and molecular diagnostics markets by enabling hospitals, physicians and other providers to save lives and fight disease. PositiveID also markets Caregiver(R), the first FDA-cleared non-contact thermometer that uses infrared technology.
EXPONENTIAL GROWTH FACTOR:
In the midst of growth investors swarming to the health care and defense sectors, PositiveID Corporation (OTCQB: PSID) recently announced the acquisition of E-N-G Mobile Systems (“ENG”), a leader in mobile labs, homeland security and communications vehicles. ENG has been successfully producing technology vehicles for 25 years, with a strong market share recording an average $4 million in revenue annually for the past decade. ENG’s primary focus is the production of mobile biological and chemical labs. ENG currently has over 400 mobile labs in the field capable of testing for chemical, radiological, biological, nuclear and explosive agents present in the environment. ENG’s track record as a company shows a history of strong leadership, steady growth, and an ability to translate sophisticated ideas into user-friendly tools.
PositiveID, the developer of Firefly Dx, a compact, rapid biological detection system, plans to meld ENG’s technology, design and production expertise with PSID‘s biological detection and diagnostic products to create state-of-the-art mobile lab vehicles. Firefly Dx is a point-of-need, hand-held system designed to deliver molecular diagnostic results using real-time PCR chemistry in less than 30 minutes. The Firefly Dx prototype system can identify an expansive range of biological agents including viruses and bacteria, from influenza to MRSA to E. coli and more, with the use of polymerase chain reaction chemistry, which rapidly amplifies DNA. PositiveID’s Chairman and CEO, William J. Caragol, said, “2015 was a terrific year for PositiveID where we made tremendous strides in several key areas. In December 2015 we made two highly synergistic and strategic acquisitions. One of those acquisitions was E-N-G Mobile Systems, Inc. Our bio-detection products, coupled with their mobile biological and chemical labs, creates another strong foundation towards substantial revenue growth for PSID in 2016. In addition, they bring a high profile book of current customers that include major federal government labs and Fortune 100 companies, along with state and government agencies.”
2016 is expected to be a pivotal year for PSID as they integrate ENG and change the way field testing can be done in terms of location and the time it takes to return results. It is not hard to imagine that countries around the world will look to embrace the convenience of the fully functional mobile labs. In the case of infectious diseases alone, countless live can be saved as detection becomes faster and safer.
The bio-detection market has grown exponentially in recent years. The global PCR market is projected to reach approximately $27.4 billion by 2015, according to Research and Markets’ “Polymerase Chain Reaction (PCR) – Products/Tools – A Global Market Watch, 2009-2015” report. The synergy created by combining the innovative biotechnology of these two companies has the potential to catapult the relatively young, PSID to revenues of $5-6 million in 2016. With revenues totaling $1 million in 2014 and then jumping to an expected $3 million in 2015, this could be an ideal time for investors to jump on this hot, emerging company, while the market cap has not yet shown the positive effects of this merger.
|
